KYTHERA Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of prescription products for the aesthetic medicine market in the United States and internationally. Its product candidate, ATX-101, is an injectable drug in late-stage clinical development for the reduction of submental fat. The company also maintains research interest in hair and fat biology, pigmentation modulation, and facial contouring. It has a collaboration arrangement with Bayer Consumer Care AG and a related collaboration agreement with Bayer Consumer Care AG’s affiliate, Intendis GmbH to develop and commercialize ATX-101 outside the United States and Canada. The company was formerly known as AESTHERx, Inc. and changed its name to KYTHERA Biopharmaceuticals, Inc. in July 2006. KYTHERA Biopharmaceuticals, Inc. was founded in 2004 and is headquartered in Westlake Village, California. Kythera Biopharmaceuticals, Inc. operates as a subsidiary of Allergan plc.